Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study

Arévalo, J. Fernando; Sánchez, J. García; Garcia, Reinaldo A.; Wu, Lihteh; Berrocal, María H.; Rodriguez, Francisco J.; Rodríguez, Álvaro; Novoa, Liliana Andrea; Garcia-Amaris, Rafael A.

doi:10.1007/s00417-007-0633-2

Cited by 11 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results suggested that ICG can be used as a weak photosensitizer for choroidal neovascularisation therapy. Further studies of Navajas et al ( 17 ) and Arevalo et al ( 18 , 19 ) revealed that ICG can be used as a weak photosensitizer in the clinical treatment of cataracts and some other ophthalmic diseases. However, there are relatively fewer studies on ICC treatment of CCH.…”

Section: Discussionmentioning

confidence: 98%

Application of ICG-enhanced thermocoagulation method and photodynamic therapy in circumscribed choroidal hemangioma

et al. 2018

View full text Add to dashboard Cite

The present study was designed to compare the effect of indocyanine green (ICG)-enhanced laser (810 nm) thermocoagulation method and photodynamic therapy (PDT) on circumscribed choroidal hemangioma (CCH). A total of 36 patients (36 pair of eyes) diagnosed with CCH in the Ocular Fundus Disease Center of The Affiliated Hospital of Medical College of Ningbo University from June 2010 to January 2016 were selected and randomly divided into two groups. ICG-enhanced thermocoagulation was used to treat 18 patients (18 pair of eyes), and PDT was used to treat the remaining 18 patients (18 pair of eyes). The best corrected visual acuity of the affected eyes was observed before and after treatment, and changes in the tumor were observed through ocular fundus photochromes under the ophthalmoscope. The changes in tumor size and height were examined through B-scan ultrasonography. The changes in serous retinal fluid were examined by optical coherence tomography (OCT). A total of 36 patients were followed-up for 3, 7, 11 and 24 weeks after laser therapy with an average of 18 weeks. It was seen that the subretinal serous exudation disappeared in 36 patients through the fundus examination after treatment, and B-scan ultrasonography showed that the tumor size was reduced. Among 18 patients undergoing ICG-enhanced thermocoagulation treatment, the visual acuity of 72.2% of them was improved, while that of the remaining 27.8% was stable, and there were no patients with decreased visual acuity; the fundus observation showed that when tumor atrophy occurred, the tumor turned white accompanied with mild pigment disorders, but retinal and choroidal normal vessels were not damaged. Among 18 patients undergoing PDT treatment, the visual acuity of 44.4% was increased, that of 50% was stable, and that of 5.6% of the patients was decreased; through fundus observation, tumor atrophy scars and alignment, a large number of hyperplasia or pigment loss and partial vascular occlusion could be seen. The results indicated that in the treatment of CCH, ICG-enhanced laser (810 nm) thermocoagulation and PDT can lead to tumor atrophy and promote the absorption of exudation. However, the damage of ICG-enhanced laser thermocoagulation to normal fundus tissues is significantly smaller than that of PDT, and the former has higher safety.

show abstract

Section: Discussionmentioning

confidence: 98%

Application of ICG-enhanced thermocoagulation method and photodynamic therapy in circumscribed choroidal hemangioma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…(Chopdar, 1978;Friedman et al, 1993;Gass and Blodi, 1993;Hutton et al, 1978;Kiraly and Nasemann, 1995;Lowe et al, 1998;Park et al, 1997;Stoffelns et al, 2010;Watzke et al, 2005) Obsolete due to side effects (Gass and Blodi, 1993;Lee, 1996;Watzke et al, 2005) Photodynamic ( Alldredge and Garretson, 2003;Cakir et al, 2006;Maguluri et al, 2007;Maia Junior et al, 2006;Martinez, 2003;Wu et al, 2008) --+ Indocyanine green-mediated photothrombosis (Arevalo et al, 2007) Posterior juxtascleral administration of steroids…”

Section: Abbreviationsmentioning

confidence: 99%

Macular Telangiectasia Type 2

Heeren

Holz

Issa

2013

Microperimetry and Multimodal Retinal Imaging

View full text Add to dashboard Cite

Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangiectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyperfluorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal disruption of the photoreceptor inner segment-outer segment border, hyporeflective cavities at the level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2 shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplementation. There have been various therapeutic approaches with limited or no efficacy. Recent clinical trials with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF in the pathophysiology of the disease, but have not shown significant efficacy, at least for the nonneovascular disease stages. Recent progress in structure-function correlation may help to develop surrogate outcome measures for future clinical trials.In this review article, we summarize the current knowledge on macular telangiectasia type 2, including the epidemiology, the genetics, the clinical findings, the staging and the differential diagnosis of the disease. Findings using retinal imaging are discussed, including fluorescein angiography, OCT, adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autofluorescence, as are the findings using visual function testing including visual acuity and fundus-controlled microperimetry. We provide an overview of the therapeutic approaches for both non-neovascular and neovascular disease stages and provide a perspective of future directions including animal models and potential therapeutic approaches.

show abstract

VEGF-Inhibition in Macular Telangiectasia Type 2

Issa

Holz

2016

Anti-Angiogenic Therapy in Ophthalmology

View full text Add to dashboard Cite

Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study

Abstract: Combined IMP and IVTA may provide stability or improvement in BCVA and fundus findings in eyes with macular edema secondary to IPFT group 2A without CNV at a minimum follow-up of 12 months.

Cited by 11 publications

References 32 publications

Application of ICG-enhanced thermocoagulation method and photodynamic therapy in circumscribed choroidal hemangioma

Application of ICG-enhanced thermocoagulation method and photodynamic therapy in circumscribed choroidal hemangioma

Macular Telangiectasia Type 2

VEGF-Inhibition in Macular Telangiectasia Type 2

Contact Info

Product

Resources

About